Stories about Diabetes

Subscribe to Diabetes

11.12.2020 – 13:08

Roche Diabetes Care
Roche teams up with Diabeloop to advance the management of insulin pump therapy

Basel (ots/PRNewswire) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes1. - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management ...

more
11.12.2020 – 07:00

Roche Diabetes Care
Roche teams up with Diabeloop to advance the management of insulin pump therapy

Basel (ots) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management (iPDM). Roche ...

more
01.12.2020 – 09:12

Grünenthal Group
Grünenthal agrees to acquire European rights to CRESTOR [TM] (rosuvastatin) from AstraZeneca

Aachen, Germany (ots) - Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights (excluding Spain and the UK) to CRESTOR[TM] (rosuvastatin) and its associated brands for a total consideration of up to US$ 350 million. CRESTOR(TM) is among the leading statin products in Europe and is ...

more
13.11.2020 – 08:00

ForaCare Suisse AG

FORA® 6 Blood Glucose Monitors Help Diabetic Patients Monitor COVID-19 Risks

more
02.11.2020 – 17:12

Helmholtz Zentrum München

Follow your gut: How farms protect from childhood asthma

Follow Helmholtz Munich on Twitter

more
10.08.2020 – 22:00

Ascensia Diabetes Care; PHC Holdings Corporation
PHC Holdings Corporation and Ascensia Diabetes Care Announce Financing Agreement and Exclusive Global Commercial Agreement With Senseonics

Tokyo and Basel, Switzerland (ots/PRNewswire) - PHC Holdings Corporation and Ascensia Diabetes Care, a PHC Group company, today announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose ...

more
21.07.2020 – 16:00

Grünenthal Group
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

Aachen, Germany & Morristown, N.J. (ots) - - Neuropathic pain associated with diabetic peripheral neuropathy is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20201. - QUTENZA® is the first and only topical, non-systemic, non-opioid pain ...

more
06.07.2020 – 13:52

Technische Universität München
Gut bacteria improve type 2 diabetes risk prediction

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36118/ Images for journalists: https://mediatum.ub.tum.de/1552269 NEWS RELEASE Large-scale study with more than 4000 participants at ZIEL - Institute for Food & Health Gut bacteria improve type 2 diabetes risk ...

more
13.06.2020 – 17:00

Novo Nordisk A/S
Switching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice

Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...

more
10.06.2020 – 17:00

International Atherosclerosis Society
International Atherosclerosis Society Issues Call to Action to Improve Lipid Management Based on Survey Results to Address Patients' Residual Risk

Milan (ots/PRNewswire) - Article and slides can be found at https://www.athero.org/activities/survey or contact Karen Foy (karen.foy@athero.org) A new survey by the International Atherosclerosis Society (IAS) provided a 'snapshot' of the gaps in knowledge among clinicians that limit best practice. This web-based ...

more
10.06.2020 – 10:14

Galderma
Galderma Global Research Reveals Struggles of People With Rosacea and Psoriasis of the Face Experiencing a Lack of Control and Impact on Mental Wellbeing

Lausanne, Switzerland (ots/PRNewswire) - Healthcare professionals (HCPs) encouraged to investigate true impacts beyond the visible, empower patients with knowledge and aim for 'clear' (IGA 0) skin to improve outcomes A new expert-authored Galderma report released today reveals the true extent of the hidden burden of ...

more
27.04.2020 – 17:22

Helmholtz Zentrum München

2
Beta cells from stem cells: Potential for cell replacement therapy

Read the study

more
31.03.2020 – 18:00

Novo Nordisk A/S
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...

more
04.03.2020 – 08:59

Stada Arzneimittel
Press release: STADA takes clear lead in Russian consumer healthcare sector

Press release STADA takes clear lead in Russian consumer healthcare sector - STADA has today closed a US$660 million transaction of a Russian brand portfolio from Takeda. STADA has reinforced its position as the leading foreign investor in the Russian pharmaceutical industry. - The acquisition of around ...
One document
more
19.02.2020 – 07:30

Gerresheimer AG
Gerresheimer sets foundation for profitable growth in 2019

Duesseldorf (ots) - -Foundation for sustainable and profitable growth laid in 2019: Annual revenue growth in the mid-single-digit percentage range targeted for 2020 and subsequent years -2019 operating targets met: Underlying revenues reach EUR 1.40bn and underlying adjusted EBITDA EUR 293m -Further increase in proposed dividend to EUR 1.20 per share from ...
One document
more
09.01.2020 – 09:03

Technische Universität München
Gene network helps to turn white fat into beneficial calorie burning fat

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/ High resolution images: https://mediatum.ub.tum.de/1524726 NEWS RELEASE A new approach to treating overweight and obesity Gene network helps to turn white fat into beneficial calorie ...

more
18.12.2019 – 14:07

Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

more
04.12.2019 – 09:01

ForaCare Suisse AG
ForaCare Suisse AG Launches "Lab in the Pocket" Technology

ST. GALLEN, Switzerland (ots) - Innovative FORA 6 GTel Capability Provides 6 Tests with Single Device, SIM Direct-to-Telehealth Connectivity ForaCare Suisse AG announced the launch of its FORA 6 GTel multi-functional monitoring device with its new "Lab in the Pocket" technology (available on the GTel model and FORA 6 Series products). The innovative 6-in-1 monitoring technology provides seamless 3G/4G data transmission of ...

more
19.11.2019 – 13:38

Gerresheimer AG
New Focus in Project Portfolio of Gerresheimer Subsidiary Sensile Medical

Dusseldorf, Germany (ots/PRNewswire) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed ...

more
19.11.2019 – 12:00

Gerresheimer AG
New focus in project portfolio of Gerresheimer subsidiary Sensile Medical

Duesseldorf (ots) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed a contract with the ...

more
17.09.2019 – 15:45

Novo Nordisk A/S
Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic® was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and ...

more
06.11.2018 – 09:02

Primary Care Diabetes Europe (PCDE)
Primary Care Diabetes Europe Issues Call to Action Against Clinical Inertia in the Treatment of Type-2 Diabetes

Ekeren, Belgium (ots/PRNewswire) - Research identifies lack of primary care physician adherence to treatment guidelines among the challenges to optimal care for patients with type-2 diabetes Primary Care Diabetes Europe (PCDE) today issued a call to action challenging primary care physicians and other healthcare ...

more
28.09.2018 – 10:01

Novo Nordisk A/S
International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...

more

1